Details of the Drug
General Information of Drug (ID: DMFG2S5)
Drug Name |
2-(2-chlorophenyl)-2-morpholinoethanamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
866782-01-6; 2-(2-Chlorophenyl)-2-morpholin-4-ylethylamine; 2-(2-chlorophenyl)-2-(morpholin-4-yl)ethan-1-amine; 2-(2-chlorophenyl)-2-morpholinoethanamine; CHEMBL382382; 4-Morpholineethanamine,b-(2-chlorophenyl)-; 2-(2-chlorophenyl)-2-morpholin-4-ylethanamine; 2-(2-Chlorophenyl)-2-morpholinoethylamine; 2-(2-Chlorophenyl)-2-(morpholin-4-yl)ethylamine; beta-phenethylamine 6; AC1MZFUY; AC1Q53NI; SCHEMBL8276869; CTK5F7083; BDBM11556; DCA-S02-0; DTXSID90397254; MolPort-001-760-150; KS-000029ZH; 4759AH; SBB073200; AR3509
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 240.73 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||